ALOXI (palonosetron), injectable antiemetic

No clinical benefit demonstrated in the prevention of nausea and vomiting caused by cancer chemotherapy in children aged > 1 month by comparison with ondansetron.

• ALOXI 250 µg now has Marketing Authorisation in paediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.
• It is the first setron to have been granted Marketing Authorisation in infants aged between 1 and 6 months. Other setrons are used in this age group, but off-label.  There are only very limited clinical data in children under 2 years of age, particularly in infants aged between 1 and 6 months.